Purple Biotech Ltd
Change company Symbol lookup
Select an option...
PPBT Purple Biotech Ltd
ADXS Advaxis Inc
NVVE Nuvve Holding Corp
ICCC ImmuCell Corp
MET MetLife Inc
FAST Fastenal Co
PFTA Portage Fintech Acquisition Corp
SMLP Summit Midstream Partners LP
GFOR Graf Acquisition Corp IV
DUOT Duos Technologies Group Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Israel
Company profile

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

This security is an American depositary receipt
ADR Fees
American Depositary Receipt (ADR) Fee

ADR fees charged by custodial banks normally average from 1 to 3 cents per share. Other country fees might apply. To read more, see the Exception Fees tab at Brokerage Fees

Price
Delayed
$1.99
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 214 shares is on pace to be much lighter than PPBT's 10-day average volume of 36,319 shares.

214
Latest Earnings Missed Consensus (Q3 ending 09/2022)Next Earnings Announcement
Q3
Announced November 8, 2022
-$0.27Q3 Consensus
of 2 analysts
-$0.21Difference from
consensus
-28.57%
Q4 Earnings
will announce
(Unconfirmed) February 7, 2023

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

PPBT's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.